The deal for the privately held U.K.-based biotechnology firm will help bolster Novartis’s oncology capabilities.

The latest proposal—the fifth from Castlelake—stands at £6.90 a share. This is up from a previous proposal of £6.50 a share.

The move is part of Seoul’s broader push to secure developed-market status from global index provider MSCI.

The decision by FIFA to rescind U.S. striker Folarin Balogun’s one-game suspension followed a rapid response from the Trump ...

Netanyahu’s bid to survive as Israel’s long-serving prime minister is running up against a groundswell of support for Gadi ...

Santa Monica is starting to bounce back from a state of “fiscal distress” including financial woes, declining international ...

Brazil entered its Round of 16 tilt on Sunday with the pedigree of a record five World Cup championships. But underdog Norway ...

As public opinion of AI has shifted into the negative, warnings of mass employment reductions have also diminished.

Chinese-European startup Windrose Technology faces questions from ex-employees about its future ...

The regulator initially denied Jared Isaacman’s request to fly in the Freedom 250 celebration, calling the aircraft too ...

Read on-business on The Wall Street Journal ...

As AI disrupts traditional career paths, these college students are skipping corporate internships for San Francisco hacker ...